Gilead Sciences, Inc. – Consensus ‘buy’ rating and 9.4% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Gilead Sciences, Inc. which can be found using ticker (GILD) now have 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 109.4 and 66.96 and has a mean target at $85.47. Given that the stocks previous close was at $78.15 this indicates there is a potential upside of 9.4%. It’s also worth noting that there is a 50 day moving average of $76.40 and the 200 day moving average is $79.40. The market capitalization for the company is 97.67B. The current share price for the company is: 78.39 USD

The potential market cap would be $106,823,526,588 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 18.02, revenue per share of 21.87 and a 9.77% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search